Retatrutide Dose

Author

Retatrutide Dose Editorial Desk

The editorial staff of OX RESEARCH LTD. It writes every page of this site and signs as a desk.

Published 23 Sept 2026
Three sealed OXpeptides Retatrutide research vials, crimp caps and white lyophilised cake, on a white background

Who the desk is

The Retatrutide Dose Editorial Desk is the editorial staff of OX RESEARCH LTD, a company registered under number 17464288. OX RESEARCH LTD also runs OXpeptides, which sells retatrutide for research use. That is a financial interest in the subject of this site. It is stated here and on the About page.

Pages carry the desk's name, with no individual byline. The desk is not a clinic. No page on this site is presented as medically reviewed, and nothing here is medical advice or a dosing recommendation. Retatrutide is an investigational compound, not approved by the FDA or the EMA, and the doses on this site are the doses written in published trials.

What it reads

The desk works from primary sources only. They are the peer-reviewed retatrutide papers in the New England Journal of Medicine, The Lancet, Cell Metabolism, Nature Medicine, The Lancet Diabetes and Endocrinology and Diabetes, Obesity and Metabolism, and the ClinicalTrials.gov registrations behind those trials. At the last update the site cites 10 papers with a DOI and 7 registry entries with an NCT number, all listed on the About page.

Press releases, conference abstracts without a paper, news stories, forum posts and supplier claims are never used as the source of a number.

How it checks a number

A figure is read in the paper or the registry entry itself before it goes on a page. Each DOI is resolved on CrossRef and each NCT number on ClinicalTrials.gov; a source that does not resolve is dropped, together with the claim that rested on it. The figure is then written with its population, dose, time point and comparator, so a reader can find it in the source.

Drafting and checking are assisted by software, including language models. The desk checks every figure against the primary source before publication, and an automated test resolves every DOI and NCT number before each release. When the papers say nothing on a question, such as missed doses or what happens after stopping, the page states that no published figure exists.

Pages signed by the desk

Each page below is written and revised by the desk. The dates are the real dates of first publication and of the last revision.

Corrections and contact

If a figure on this site does not match its source, write to editor@retatrutidedose.com with the page and the figure concerned. Corrections are made on the page itself and its updated date changes; a correction that changes a conclusion is noted at the foot of the page. New peer-reviewed dose data, the TRIUMPH phase 3 results in particular, is added once it carries a DOI. The rules in full are in the editorial policy.